Literature DB >> 28474991

High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma.

Daiki Murata1, Yohei Mineharu1, Yoshiki Arakawa1, Bin Liu1, Masahiro Tanji1, Makoto Yamaguchi1, Ko-Ichi Fujimoto1, Nobuyuki Fukui1, Yukinori Terada1, Ryuta Yokogawa1, Maki Yamaguchi2, Sachiko Minamiguchi2, Susumu Miyamoto1.   

Abstract

OBJECTIVE Medulloblastoma is a type of malignant tumor arising in the cerebellum. The clinical importance of programmed cell death 1 ligand-1 (PD-L1) expression in medulloblastoma remains unknown. The aim of the present study was to examine the expression of PD-L1 and tumor-infiltrating T cells, and to evaluate their relationships to the prognosis of patients with medulloblastoma. METHODS The authors immunohistochemically analyzed PD-L1 expression and CD3+ and CD8+ lymphocyte infiltrations in tumor specimens from 16 patients with medulloblastoma. RESULTS High expression of PD-L1 was observed in 9 (56.3%) of 16 samples studied. High expression of PD-L1 was associated with low infiltrations of CD3+ or CD8+ lymphocytes. Patients with high expression of PD-L1 had shorter progression-free survival and overall survival times than those with low expression (p = 0.076 and p = 0.099, respectively). In addition, patients with high expression of PD-L1 and with low infiltration of CD8+ lymphocytes had a significantly worse outcome, with a 5-year survival rate of 15%, as compared with the other patients, who had a 5-year survival rate of nearly 90% (p = 0.0048 for progression-free survival and p = 0.010 for overall survival). CONCLUSIONS These findings indicate that PD-L1 expression was associated with a reduced infiltration of CD8+ T cells and poor prognosis in human medulloblastoma.

Entities:  

Keywords:  OS = overall survival; PD-L1; PD-L1 = programmed cell death 1 ligand–1; PFS = progression-free survival; antitumor immunity; lymphocyte; medulloblastoma; oncology; prognosis; programmed cell death 1 ligand–1

Mesh:

Substances:

Year:  2017        PMID: 28474991     DOI: 10.3171/2016.11.JNS16991

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  20 in total

1.  PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.

Authors:  Kihwan Hwang; Eun Jung Koh; Eun Jin Choi; Tae Hee Kang; Jung Ho Han; Gheeyoung Choe; Sung-Hye Park; Jennifer Holmes Yearley; Lakshmanan Annamalai; Wendy Blumenschein; Manjiri Sathe; Terri McClanahan; Hun Jung; Kyu-Chang Wang; Seung-Ki Kim; Chae-Yong Kim
Journal:  J Neurooncol       Date:  2018-05-05       Impact factor: 4.130

2.  Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.

Authors:  Dai Kamamoto; Kentaro Ohara; Yohei Kitamura; Kazunari Yoshida; Yutaka Kawakami; Hikaru Sasaki
Journal:  J Neurooncol       Date:  2018-04-19       Impact factor: 4.130

Review 3.  Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies.

Authors:  Christopher Montemagno; Frédéric Luciano; Gilles Pagès
Journal:  Methods Mol Biol       Date:  2022

4.  High expression of Toll-like receptor 7 is a survival factor in pediatric medulloblastoma.

Authors:  Lourdes Alvarez-Arellano; Pilar Eguía-Aguilar; Patricia Piña-Sánchez; Nadia González-García; Alam Palma-Guzman; Mario Perezpeña-Diazconti; Carmen Maldonado-Bernal
Journal:  Childs Nerv Syst       Date:  2021-09-04       Impact factor: 1.475

Review 5.  Immune profiling of pediatric solid tumors.

Authors:  Rachael L Terry; Deborah Meyran; David S Ziegler; Michelle Haber; Paul G Ekert; Joseph A Trapani; Paul J Neeson
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

6.  Subgroup-specific immune and stromal microenvironment in medulloblastoma.

Authors:  Michael Bockmayr; Malte Mohme; Frederick Klauschen; Beate Winkler; Jan Budczies; Stefan Rutkowski; Ulrich Schüller
Journal:  Oncoimmunology       Date:  2018-05-24       Impact factor: 8.110

7.  CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma.

Authors:  Jakob Nikolas Kather; Christian Hörner; Cleo-Aron Weis; Thiha Aung; Christian Vokuhl; Christel Weiss; Monika Scheer; Alexander Marx; Katja Simon-Keller
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

8.  Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma.

Authors:  Jeroen F Vermeulen; Wim Van Hecke; Elisabeth J M Adriaansen; Mieke K Jansen; Rianne G Bouma; José Villacorta Hidalgo; Paul Fisch; Roel Broekhuizen; Wim G M Spliet; Marcel Kool; Niels Bovenschen
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

9.  PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.

Authors:  Bin Liu; Yoshiki Arakawa; Ryuta Yokogawa; Shinya Tokunaga; Yukinori Terada; Daiki Murata; Yasuzumi Matsui; Ko-Ichi Fujimoto; Nobuyuki Fukui; Masahiro Tanji; Yohei Mineharu; Sachiko Minamiguchi; Susumu Miyamoto
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

10.  PD-L1 expression in medulloblastoma: an evaluation by subgroup.

Authors:  Allison M Martin; Christopher J Nirschl; Magda J Polanczyk; W Robert Bell; Thomas R Nirschl; Sarah Harris-Bookman; Jillian Phallen; Jessica Hicks; Daniel Martinez; Aleksandra Ogurtsova; Haiying Xu; Lisa M Sullivan; Alan K Meeker; Eric H Raabe; Kenneth J Cohen; Charles G Eberhart; Peter C Burger; Mariarita Santi; Janis M Taube; Drew M Pardoll; Charles G Drake; Michael Lim
Journal:  Oncotarget       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.